98%
921
2 minutes
20
There is limited evidence supporting the recommendation that drivers with insulin-treated diabetes need to start journeys with glucose >90 mg/dL. Glucose levels of drivers with type 1 diabetes were monitored for 3 weeks using masked continuous glucose monitoring (CGM). Eighteen drivers (median [IQR] age 40 [35, 51] years; 11 men) undertook 475 trips (duration 15 [13, 21] min). Hypoglycemia did not occur in any trip starting with glucose >90 mg/dL (92%; = 436). Thirteen drivers recorded at least one trip (total = 39) starting with glucose <90 mg/dL. Among these, driving glucose was <70 mg/dL in five drivers (38%) during 10 trips (26%). Among five drivers (28%), a ≥ 36 mg/dL drop was observed within 20 min of starting their journey. Journey duration was positively associated with maximum glucose change. These findings support current guidelines to start driving with glucose >90 mg/dL, and to be aware that glucose levels may change significantly within 20 min. A CGM-based, in-vehicle display could provide glucose information and alerts that are compatible with safe driving. Clinical Trial Registration number: ACTRN12617000520336.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1089/dia.2021.0460 | DOI Listing |
Cell Mol Biol (Noisy-le-grand)
September 2025
M-DT1, Roquefort-les Pins, France.
To date, the closed-loop system represents the best commercialized management of type 1 diabetes. However, mealtimes still require carbohydrate estimation and are often associated with postprandial hyperglycemia which may contribute to poor metabolic control and long -term complications. A multicentre, prospective, non-interventional clinical trial was designed to determine the effectiveness of a novel algorithm to predict changes in blood glucose levels two hours after a usual meal.
View Article and Find Full Text PDFZhong Nan Da Xue Xue Bao Yi Xue Ban
May 2025
Department of Laboratory Animal Science, Xiangya School of Medicine, Central South University, Changsha 410013, China.
Objectives: Recent evidence suggests that the gut may be a primary site of metformin action. However, studies on the effects of metformin on gut microbiota remain limited, and its impact on gut microbial metabolites such as short-/medium-chain fatty acids is unclear. This study aims to investigate the effects of metformin on gut microbiota, short-/medium-chain fatty acids, and associated metabolic benefits in high-fat diet rats.
View Article and Find Full Text PDFCarbohydr Polym
November 2025
Jiangsu Key Laboratory of Crop Genetics and Physiology, Key Laboratory of Plant Functional Genomics of the Ministry of Education, College of Agriculture, Yangzhou University, Yangzhou 225009, Jiangsu Province, China; Co-Innovation Centre for Modern Production Technology of Grain Crops, Yangzhou Univ
Glycogen is a complex branched glucose polymer that serves as energy reservoir in animals and some bacteria; it has also been synthesized in vitro. It comprises small β particles linked in large aggregates termed α particles. Theory, based on the evolutionary processes which cause these particles to be formed, suggests that if all ingredients for in vitro particle synthesis were added to a suspension of α particles, then these will grow to a steady-state size distribution, after which new particles will be formed.
View Article and Find Full Text PDFBMJ Open
September 2025
Neath Port Talbot Hospital, Port Talbot, Wales, UK.
Introduction: Gestational diabetes mellitus (GDM) is common in pregnancy and is increasing in prevalence. It is associated with an increased risk of maternal and perinatal complications if not diagnosed and managed early. Most guidelines suggest making a diagnosis of GDM using an oral glucose tolerance test (OGTT) between 24 and 28 weeks of pregnancy at which stage there still is an increased risk of complications.
View Article and Find Full Text PDFJ Clin Endocrinol Metab
September 2025
Developmental Endocrinology Research Group, University of Glasgow, Royal Hospital for Children, Glasgow, UK.
Objective: To understand the frequency and trends in reported outcomes of safety and effectiveness for recombinant human growth hormone (rhGH) therapy for growth hormone deficiency (GHD) in childhood.
Methods: A systematic review was performed in seven English and Chinese language databases. Eligibility criteria included all studies published between 2003 and 2022, with participants who started rhGH before the age of 16 years for GHD.